Vorinostat Study for Graft vs Host Disease Prevention

This study focuses on children, teens, and young adults undergoing a special type of transplant, called allogeneic blood or marrow transplant (BMT). A BMT is a medical procedure where you receive new blood-forming cells from a donor. The study aims to find the best dose of a drug called Vorinostat which might help prevent a condition called Graft vs Host Disease (GVHD). GVHD can happen after a transplant when the donor cells attack the recipient's body.

• Participants are aged 3 to 39 and will receive Vorinostat along with standard GVHD prevention treatments.
• The study requires participants to be healthy enough to take part, have a life expectancy over six months, and able to take oral medications.
• Participants must use birth control during and after the study due to unknown risks of Vorinostat on unborn babies.

Participation involves following study procedures and visits, and you may not join if you're on another GVHD trial or have certain health conditions. If you qualify, this study could help advance treatments for GVHD prevention.